Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Sunshine Biopharma (SBFM) over the last 4 years, with Dec 2024 value amounting to -$7.32.

  • Sunshine Biopharma's EPS (Weighted Average and Diluted) rose 78.00% to -$0.44 in Q1 2025 from the same period last year, while for Mar 2025 it was -$102.98, marking a year-over-year decrease of 3.47%. This contributed to the annual value of -$7.32 for FY2024, which is 97.92% up from last year.
  • Latest data reveals that Sunshine Biopharma reported EPS (Weighted Average and Diluted) of -$7.32 as of FY2024, which was up 97.92% from -$351.36 recorded in FY2023.
  • In the past 5 years, Sunshine Biopharma's EPS (Weighted Average and Diluted) registered a high of -$1.76 during FY2022, and its lowest value of -$351.36 during FY2023.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$7.32 (2024), whereas its average is -$120.15.
  • Per our database at Business Quant, Sunshine Biopharma's EPS (Weighted Average and Diluted) tumbled by 19,863.64% in 2023 and then skyrocketed by 97.92% in 2024.
  • Over the past 4 years, Sunshine Biopharma's EPS (Weighted Average and Diluted) (Yearly) stood at -$4.76 in 2021, then spiked by 63.03% to -$1.76 in 2022, then slumped by 19,863.64% to -$351.36 in 2023, then surged by 97.92% to -$7.32 in 2024.